Nov 17, 2021 | biomarkers, precision medicine |
when we talk about mutations, this represents a very small amount of cancer patients – in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively]. however, this actually represents respectively-...
